Dr Reddy's Infuses Life Into XenoPort's Psoriasis Drug
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories will take XenoPort's clinical-stage oral psoriasis NCE, XP23829, further in the US, infusing new hope in the prodrug of monomethyl fumarate (MMF) that has seen some safety issues in earlier studies and faces significant competition in the space.